Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease (Abstract/Comunicazione in atti di convegno)

Type
Label
  • Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease (Abstract/Comunicazione in atti di convegno) (literal)
Anno
  • 2011-01-01T00:00:00+01:00 (literal)
Alternative label
  • F. Sbrana, M. Puntoni, F. Bigazzi, S. Vicari, E. Grisanti, A. Ragusa, M. Pianelli, R. Luciani, T. Sampietro (2011)
    Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease
    in 25. congresso nazionale SISA, Roma, 30 novembre - 3 dicembre 2011
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • F. Sbrana, M. Puntoni, F. Bigazzi, S. Vicari, E. Grisanti, A. Ragusa, M. Pianelli, R. Luciani, T. Sampietro (literal)
Pagina inizio
  • 95 (literal)
Pagina fine
  • 96 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • ID_PUMA: cnr.ifc/2011-B6-012 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.sisa.it/index.php?class=Comp&className=Content&op=Show¶m=cid,367,preview,0 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 2 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 3 (literal)
Note
  • Abstract (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Fondazione CNR, Regione Toscana \"Gabriele Monasterio\", Pisa, Italy ; CNR Institute of Clinical Physiology of Pisa, Italy (literal)
Titolo
  • Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease (literal)
Abstract
  • Background: Cardiovascular disease is the principal cause of premature mortality and morbidity in Europe. Patients with familial hypercholesterolemia are at particularly increased risk and, despite lipid-lowering therapy, continue to experience cardiovascular events. Currently, for these patients a new treatment option is represented by extended-release niacin/laropiprant (ERN/LRPN). Material and Methods: We followed-up for 16 weeks a group of 23 familial hypercholesterolemic patients (mean age 61±7 years, 74% male) with chronic coronary artery disease and ERN/LRPN added on top of maximally tolerated lipid-lowering therapy. ERN/LRPN was administered at the dose of 1 gr/day for the first 4 weeks and then at 2 gr/day for the remaining period. Clinical examination and blood sampling (including lipid profile, renal and hepatic function) were performed at baseline, after 4 weeks, at the end of follow-up, and in the case of eventual clinical manifestations. Results: During follow-up, 14 patients discontinued therapy due to side effects (headache, asthenia, and gastrointestinal disorders in 4 patients, muscle aches and CK increase in 3 patients, eruptive skin rash in 2 patients, onset of diabetes mellitus in 2 patients, dizziness associated with inability to drive in 1 patient, acute hepatitis in 1 patient and palpitations in 1 patient) and 2 patients voluntarily interrupted the therapy. In the remaining 7 patients, an improvement in lipid profile was observed (total cholesterol -14%, HDL cholesterol +7%, LDL cholesterol -16%, Triglycerides -53%, Apolipoprotein A1 +8%, Apolipoprotein B -21%, Apolipoprotein E -31%) in the absence of substantial changes in other laboratory analyses (with the exception of a non-significant increase in uric acid). Intolerable skin flushing was not observed in any patient. In addition, among patients who did report flushing, a reduction in the incidence of the episodes was observed after the first month of therapy. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it